Research
Hormonal
The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.
Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.
StrongSupportsmedium confidence
The evolution of anti-obesity pharmacotherapy has progressed from the use of high-risk agents such as amphetamines and thyroid extracts to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.
Why this rating
The claim is based on a review of existing pharmacotherapy literature.
Source
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Xingrong Feng et al. · Chinese Medical Journal · 2025
DOI 10.1097/cm9.0000000000003919
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and bile acid receptors including the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5).Strong
- The development of oral formulations such as oral Semaglutide is expected to provide convenience for patients and enhance their willingness to receive treatment.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →